Cecolin

BIOLOGICAL2 trials

Sponsors

Xiamen Innovax Biotech Co., Ltd, PATH

Conditions

CancerHepatitis E Virus InfectionHuman Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 18

Phase 3

Phase 3 Trial to Study Alternate 2-Dose Regimens of a Bivalent HPV Vaccine (Cecolin®) in Young Girls

Active, not recruitingPACTR202008675647876

Start: 2020-12-01Target: 1025Updated: 2026-01-27

Phase 4

Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

Xiamen Innovax Biotech Co., LtdHepatitis E Virus Infection, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18

Start: 2021-10-25End: 2023-06-10Target: 480Updated: 2022-06-13

Related Papers

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.

2025-03-193 citations